



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

August 16, 2023

James Green  
Chief Executive Officer  
Harvard Bioscience, Inc.  
84 October Hill Road  
Holliston, MA 01746-1371

**Re: Harvard Bioscience, Inc.**  
**Definitive Proxy Statement on Schedule 14A**  
**Filed April 5, 2023**  
**File No. 001-33957**

Dear James Green:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Disclosure Review Program